Skip to main content

Advertisement

SpringerLink
Log in

Introduction: advances in antiviral therapy for chronic hepatitis C infection—the influence of genotype and HIV co-infection

  • Article
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Viral Hepatitis Resource Center. [http://www.cdc.gov/ncidod/diseases/hepatitis/resource/index.htm] (Accessed 2 October 2006)

  2. Manns MP et al. (2006) Treating viral hepatitis C: efficacy, side effects and complications. Gut 55: 1350–1359

    Article  CAS  Google Scholar 

  3. Liang TJ et al. (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296–30555

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. University of Miami School of Medicine, 1500 NW 12 Avenue, Jackson Medical Tower E-1101, Miami, FL 33136, USA eschiff@med.miami.edu

Authors and Affiliations

  1. Division of Hepatology; and Director, ER Schiff is Leonard Miller Professor of Medicine; Chief, Center for Liver Disease, University of Miami School of Medicine, Miami, FL, USA.,

    Eugene R Schiff

  2. Division of Hepatology, Chief, Division of Hepatology,

    Eugene R Schiff

Authors
  1. Eugene R Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Eugene R Schiff acts as a consultant to Abbott, Achillion Pharmaceutical, Bayer, Bristol Myers Squibb, Cadence Pharmaceuticals, Gilead, GlobeImmune Inc., Idenix, Maxim, National Genetics Institute, Novartis, Ortho-Biotech, Pfizer, PowerMed Ltd., Prometheus, Roche Molecular, Sankyo Pharma Inc., Schering-Plough, and SciClone Pharmaceuticals. He has received grant support from Abbott, Bayer, Bristol Myers Squibb, Coley, Gilead, GlaxoSmithKline, Idenix, Ortho-Biotech, Prometheus, Roche Diagnostics, Roche Molecular, Roche Pharmaceutical, Schering-Plough, SciClone Pharmaceuticals, and Vertex Pharamceuticals. He also receives honoraria for speaking from Abbott, Bristol Myers Squibb, Giliead, GlaxoSmithKline, Idenix, Ortho-Biotech, and Schering-Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiff, E. Introduction: advances in antiviral therapy for chronic hepatitis C infection—the influence of genotype and HIV co-infection. Nat Rev Gastroenterol Hepatol 4 (Suppl 1), S1–S2 (2007). https://doi.org/10.1038/ncpgasthep0690

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0690

  • Springer Nature Limited

Search

Navigation